Page 2 - Undoing Aging News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(0) Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the appointment of Pedro M. Quintana Diez, MD as Chief Medical Officer. Pedro will be responsible for the clinical and regulatory strategy, planning, and execution of the company's clinical development plans. "We are delighted to bring someone with Pedro's impressive expertise and experience on board during this exciting time for Elastrin," said Dr. Matthias Breugelmans, CEO at Elastrin Therapeutics. "Hi...

(1) Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again. It is the latest addition to the growing portfolio of Kizoo Technology Capital, a rejuvenation biotech investor focused on reversing age-related damage on a cellular and molecular level. Elastrin's lead asset is a nanoparticle conjugated with a novel monoclonal antibody for the treatment of heart valve and vascular calcification. "Elastin fibers are critical for the homeostasis of tissues around the body, including the skin, vasculature, and pu...

$5M financing round led by Kizoo Technology Capital Fresh capital to be employed for productization, to prepare a clinical trial in organ transplantation and to expand cellvie's pipeline into rejuvenation therapies Promising initial clinical data generated at Boston Children's Hospital to be published in the Journal of Thoracic and Cardiovascular Surgery Zurich/Switzerland and Houston/USA, January 25, 2021: cellvie Inc., the leader in Therapeutic Mitochondria Transfer (TMT) and a Harvard University spin-off, closes a $5M round to advance its product pipeline, including a first application in ...